Phase 2 N=35 Insulin Resistance and Testosterone in Women
Insulin Resistance · Postmenopause
Primary: Percent Change in Free Testosterone (T) — -6.9; -35.8; 12.1 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Proportion of Participants With Grade 2-4 Toxicities — 0.63; 0.40 proportion of participants
Phase 2 N=20 Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Overall Survival (OS) — 64.7 percentage of participants
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 2 N=10 Autologous Fecal Therapy
Infectious Disease of Digestive Tract
Primary: Number of Participants With Restoration of Microbial Community Composition to the Pre-antibiotic State by 90 Days Post FMT or Saline Enema — 5; 5 Participants
Phase 2 N=90 CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Number of Patients With Response — 3; 25; 24 Participants
Phase 2 N=143 Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) Rate to Week 26 — -0.076; -0.050; -0.136 liters (L)
Phase 2 N=5 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
Adult Liver Carcinoma · Liver Cirrhosis
Primary: Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue — 0.76 Ratio
Phase 2 N=52 Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemia
Primary: Change From Baseline in RSS Total Score Over Time — -1.06; -0.73; -1.00; -0.84 score on a scale — p=< 0.0001
Phase 2 N=6 Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Pulmonary Vascular Resistance (PVR) at Three Months — -0.49 Wood units — p=0.09
Phase 2 N=141 A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change From Baseline to Week 4 in Hamilton Rating Scale for Depression (HAM-D17) Total Score — -7.1; -9.3; -6.6; -1.5 score on a scale — p=0.014
Phase 2 N=49 Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Prostate Cancer
Primary: Fold Change in Serum N-telopeptides From Baseline — 0.85; 1.34 fold change
Phase 2 N=26 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
Microvascular Angina
Primary: Change in Seattle Angina Questionnaire Score Regarding Angina Frequency — 0.70; 0.27 score on a scale
Phase 2 N=37 Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma
Asthma
Primary: FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period — 3.4305; 3.4361; 2.8209 Liters
Phase 2 N=66 PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
Carcinoma, Non Small Cell Lung
Primary: Best Overall Response (BOR) in Participants With Adenocarcinoma Histology — 0; 2; 28; 12 Participants